drugset / Trial / NCT00502567
A Study to Assess Safety, Tolerability and PK of AZD2171 and Chemotherapy on Patients With Solid Tumors
Non-randomizedSingle-groupOpen-labelTreatment
Summary
A multicentre, 2-part study to assess the safety and tolerability of once daily oral doses of AZD2171 when administered with various anticancer regimens (part A) and to confirm the tolerability of its combination with FOLFOX (part B).
Timeline
- Start
- 2005-01
- Primary completion
- 2007-11
- Completion
- 2011-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cediranib | Small molecule | — | Oral |
| Background | Cetuximab | Monoclonal antibody | — | Intravenous |
| Background | Docetaxel | Small molecule | — | Intravenous |
| Background | Irinotecan | Small molecule | — | Intravenous |
| Background | Leucovorin | Small molecule | — | Intravenous |
| Background | Oxaliplatin | Small molecule | — | Intravenous |
| Background | Pemetrexed | Small molecule | — | Intravenous |
| Background | fluorouracil | Small molecule | — | Intravenous |
Indications
No indication recorded.